Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
275 stopped studies mapped to Malignant Urinary Tract Neoplasm and descendants · 93% state a reason
Over the 275 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00089128 | Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic… | Phase 2 | terminated | Aug 5, 2004 | Medical University of South Carolina | Low accrual | Enrollment / accrual |
| NCT00268450 | Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel… | Phase 2 | terminated | Dec 22, 2005 | Medical University of South Carolina | not stated | Not stated |
| NCT03106610 | Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With… | Phase 1 | terminated | Apr 10, 2017 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT02471495 | RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE) | Phase 3 | withdrawn | Jun 15, 2015 | Medical Enterprises Europe B.V. | not stated | Not stated |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Phase 1 | terminated | Sep 7, 2015 | Celldex Therapeutics | Portfolio re-prioritization | Sponsor / business decision |
| NCT01331824 | Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory… | Phase 2 | terminated | Apr 8, 2011 | Matthew Galsky | due to a development decision by the funder | Other (stated, no rule matched) |
| NCT01234519 | A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed… | Phase 1 / Phase 2 | terminated | Nov 4, 2010 | AEterna Zentaris | Poor recruitment | Enrollment / accrual |
| NCT01710293 | Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in…(PACT CREATE 3) | N/A | withdrawn | Oct 19, 2012 | VA Office of Research and Development | Unable to obtain data needed to run the RCT; project never began recruitment | Enrollment / accrual |
| NCT02845050 | Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With…(JaNEO) | Phase 1 / Phase 2 | withdrawn | Jul 27, 2016 | Ligartis GmbH | No participants found | Other (stated, no rule matched) |
| NCT01826097 | Improving Sensitivity of Urine Cytology for Bladder Cancer | N/A | withdrawn | Apr 8, 2013 | Johns Hopkins University | not stated | Not stated |
| NCT02514408 | Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer | — | withdrawn | Aug 3, 2015 | University of Southern California | No funding | Funding |
| NCT03238664 | Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for… | N/A | withdrawn | Aug 3, 2017 | University of Southern California | No funding | Funding |
| NCT01469221 | Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive… | Phase 3 | terminated | Nov 10, 2011 | Spectrum Pharmaceuticals, Inc | Business reason | Sponsor / business decision |
| NCT02944357 | Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With… | N/A | withdrawn | Oct 25, 2016 | Mayo Clinic | not stated | Not stated |
| NCT03150836 | Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder… | Phase 2 | withdrawn | May 12, 2017 | Terence Friedlander, MD | Co-PI Albert Chang relocating to UCLA. IND will transfer to UCLA. UCSF will not participate. | Other (stated, no rule matched) |
| NCT03007771 | Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild… | Phase 1 | withdrawn | Jan 2, 2017 | Washington University School of Medicine | Decision was made to not go forward with the study | Other (stated, no rule matched) |
| NCT00003452 | Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | slow enrollment | Enrollment / accrual |
| NCT01622660 | Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic… | Phase 2 | terminated | Jun 19, 2012 | Memorial Sloan Kettering Cancer Center | Safety reasons | Safety / toxicity |
| NCT02027649 | Detection of K14 in Bladder Cancer With a Non Invasive Technique | — | terminated | Jan 6, 2014 | Corporacion Parc Tauli | Absence of positive results | Other (stated, no rule matched) |
| NCT01042795 | Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After… | Phase 2 | terminated | Jan 6, 2010 | University of Michigan | Study closed due to poor accrual | Enrollment / accrual |
| NCT02925533 | Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma… | Phase 1 | terminated | Oct 6, 2016 | Mark Pomerantz, MD | Terminated due to safety concerns. | Safety / toxicity |
| NCT01108003 | Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer… | N/A | terminated | Apr 21, 2010 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT00005047 | 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer | Phase 3 | terminated | Jan 27, 2003 | SWOG Cancer Research Network | Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility… | Safety / toxicity |
| NCT01353222 | DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | Phase 2 | terminated | May 13, 2011 | Dendreon | Administrative reasons. | Other (stated, no rule matched) |
| NCT01475266 | Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive… | Phase 2 / Phase 3 | terminated | Nov 21, 2011 | Nippon Kayaku Co., Ltd. | Sponsor's decision | Sponsor / business decision |
| NCT01410565 | Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle… | Phase 3 | terminated | Aug 5, 2011 | Spectrum Pharmaceuticals, Inc | Business reason | Sponsor / business decision |
| NCT00565227 | Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and… | Phase 1 | terminated | Nov 29, 2007 | University of Michigan Rogel Cancer Center | closed due to toxicity | Safety / toxicity |
| NCT02252393 | Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder… | N/A | withdrawn | Sep 30, 2014 | Case Comprehensive Cancer Center | waiting on surgeon training | Other (stated, no rule matched) |
| NCT02030574 | Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder… | Phase 2 | terminated | Jan 8, 2014 | Brown University | The study is being closed to accrual secondary to low accrual and an interest in opening up a… | Enrollment / accrual |
| NCT00022633 | S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer… | Phase 2 | terminated | Jan 27, 2003 | SWOG Cancer Research Network | Permanently Closed Due to Poor Accrual | Enrollment / accrual |
| NCT01339000 | Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had… | Phase 2 | terminated | Apr 20, 2011 | National Cancer Institute (NCI) | Company supplying drug declared bankruptcy, thus there was no drug supply. | Drug supply |
| NCT02718742 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy… | Phase 2 | withdrawn | Mar 24, 2016 | Mayo Clinic | not stated | Not stated |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical…(iNSITE2) | Phase 2 | terminated | Jun 24, 2015 | BIND Therapeutics | not stated | Not stated |
| NCT01916109 | Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in… | Phase 2 | terminated | Aug 5, 2013 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT01663285 | Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC) | Phase 2 | terminated | Aug 13, 2012 | University of Michigan Rogel Cancer Center | Low study participant enrollment. | Enrollment / accrual |
| NCT00974818 | Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of… | Phase 3 | terminated | Sep 10, 2009 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT00714948 | Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients… | Phase 2 | terminated | Jul 14, 2008 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT00479089 | Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer | Phase 2 | terminated | May 25, 2007 | M.D. Anderson Cancer Center | Study halted due to drug sponsor decision to not continue. | Sponsor / business decision |
| NCT00635726 | Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus… | Phase 2 | terminated | Mar 14, 2008 | Hellenic Oncology Research Group | Due to poor accrual | Enrollment / accrual |
| NCT00995488 | Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of… | Phase 2 | terminated | Oct 15, 2009 | University of Michigan Rogel Cancer Center | Terminated prematurely due to low accrual. | Enrollment / accrual |
| NCT01071928 | Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | Phase 2 | withdrawn | Feb 19, 2010 | Hoosier Cancer Research Network | Lack of efficacy of experimental treatment | Efficacy / futility |
| NCT01314664 | A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical… | — | terminated | Mar 14, 2011 | Endo USA Inc., a Keenova Therapeutics Company | Business decision, not safety related | Safety / toxicity |
| NCT01374789 | PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer(PURO) | Phase 2 | terminated | Jun 16, 2011 | WiSP Wissenschaftlicher Service Pharma GmbH | The study was terminated due to insufficient recruitment. | Enrollment / accrual |
| NCT00785694 | Recurrence of Bladder Cancer After Transurethral Resection With Hexvix | Phase 4 | withdrawn | Nov 5, 2008 | GE Healthcare | Rejected ethics approval in UK and Holland | Other (stated, no rule matched) |
| NCT00933374 | Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma(RAD001) | Phase 2 | terminated | Jul 7, 2009 | Heinrich-Heine University, Duesseldorf | delayed recruitment | Enrollment / accrual |
| NCT00918008 | A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer | — | terminated | Jun 11, 2009 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT00072137 | Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who… | Phase 1 | terminated | Nov 6, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00393796 | Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced… | Phase 2 | terminated | Oct 30, 2006 | University of Michigan Rogel Cancer Center | Low accrual | Enrollment / accrual |
| NCT00384891 | Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin… | Phase 3 | terminated | Oct 6, 2006 | Medical Enterprises Europe B.V. | slow accrual | Enrollment / accrual |
| NCT02013765 | A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial… | Phase 2 | terminated | Dec 17, 2013 | Hoffmann-La Roche | Trial was terminated prematurely because of recruitment difficulties. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 12, 2018source: clinicaltrials